20 July 2023 
EMA/CHMP/189667/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ervebo 
recombinant vesicular stomatitis virus - Zaire Ebolavirus vaccine (live) 
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Ervebo. 
The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 
The CHMP adopted an extension to the existing indication to include vaccination of infants aged 1 year 
and older. For information, the full indication for Ervebo will therefore be as follows:2  
Ervebo is indicated for active immunisation of individuals 18 years 1 year of age or older to 
protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
